Promising combo for advanced melanoma studied, but trial halted early
Disease control
Terminated
This early-phase trial tested a combination of two drugs, cabozantinib and pembrolizumab, as a first treatment for people with advanced melanoma that had spread. The goal was to see if the combination was safe and could shrink tumors. The study was stopped early, but it enrolled …
Phase: PHASE1, PHASE2 • Sponsor: John Rieth • Aim: Disease control
Last updated May 15, 2026 11:53 UTC